Last €90.74 EUR
Change Today -2.53 / -2.72%
Volume 17.9K
As of 3:56 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GIS) Snapshot

Open
€92.91
Previous Close
€93.27
Day High
€94.05
Day Low
€90.42
52 Week High
01/27/15 - €95.55
52 Week Low
04/11/14 - €45.70
Market Cap
136.9B
Average Volume 10 Days
27.8K
EPS TTM
--
Shares Outstanding
1.5B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GIS)

gilead sciences inc (GIS) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

6,100 Employees
Last Reported Date: 02/25/14
Founded in 1987

gilead sciences inc (GIS) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $746.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $884.2K
Senior Advisor
Total Annual Compensation: $810.4K
Compensation as of Fiscal Year 2013.

gilead sciences inc (GIS) Key Developments

EnvisionRx and Gilead Sciences Inc. Sign Exclusive Agreement to Help in the Fight Against Hepatitis C

EnvisionRx announced a partnership with Gilead Sciences Inc. to provide availability to HCV infection treatments Sovaldi® and Harvoni for EnvisionRx patients on an exclusive basis.

Mylan Laboratories Limited Expands Hepatitis C Licensing Agreement with Gilead Sciences Inc. to Include Investigational Pan-Genotypic Agent

Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences Inc. to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir(Sovaldi®)/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available. This agreement is in addition to the licensing and technology transfer agreement that the company entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries. The company also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.

Gilead Sciences Inc. Expands Hepatitis C Generic Licensing Deal to Include Pan-Genotypic Agent

Gilead Sciences Inc. announced that it has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The company noted that the expanded agreements will allow its India-based partnersto manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54% of the total worldwide population of individuals infected with the hepatitis C virus or HCV.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIS:GR €90.74 EUR -2.53

GIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.41 USD -0.27
AbbVie Inc $61.85 USD -1.25
AstraZeneca PLC 4,744 GBp +18.50
Eli Lilly & Co $70.97 USD 0.00
Merck & Co Inc $61.45 USD -1.11
View Industry Companies
 

Industry Analysis

GIS

Industry Average

Valuation GIS Industry Range
Price/Earnings 18.7x
Price/Sales 7.7x
Price/Book 11.7x
Price/Cash Flow 16.8x
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.